Financial Performance Highlights

Revenue: Revenue from operations stood at ₹48.9 crores in H1 FY27 compared to ₹45.2 crores in H1 FY26, representing year-on-year growth of approximately 8%.

Segment Performance: B2B business grew by 20% YoY and B2C business grew by 21% YoY. The B2G segment remained broadly stable. The revenue mix showed B2C and B2B together contributing approximately 48% of total revenue during the first half.

Profitability: EBITDA for H1 FY27 stood at ₹14.1 crores compared to ₹17.3 crores in H1 FY26. EBITDA margin was 28.9% against 38.2% in the corresponding period last year. Profit after tax stood at ₹7.8 crores compared to ₹10 crores in the previous corresponding period, with PAT margin at 16% against 22.2%.

Margin Explanation: The moderation in reported margins was attributed to: (1) Upfront expenses toward human capital, advertising, and marketing to prepare for growth phase; (2) Minor upgradation and maintenance work on existing diagnostic machines; (3) Change in geographical mix with Uttar Pradesh contribution declining and Delhi accounting for a higher share.

Finance Costs: Finance cost declined by 74% YoY to ₹0.33 crores during H1 FY27 compared to ₹1.3 crores in H1 FY26. The company fully repaid 2 loans during the period.

Leverage: Net debt-to-equity ratio stood at negative 0.1x as of September 2026 compared to negative 0.3x at the end of FY26.

Returns: Return on capital employed stood at 18.5% while return on equity was 14.2%.

Working Capital and Cash Flow

Trade Receivables: Trade receivables stood at approximately ₹64 crores as of September 2026 compared to ₹49.9 crores at the end of FY26.

Cash Flow: Cash flow from operating activities was negative ₹6.2 crores during the first half of FY27. The increase in working capital resulted in an outflow of approximately ₹17.5 crores during the period.

Receivables Composition: Approximately ₹15 crores relate to legacy COVID period transactions with Delhi and Union Territory government. These amounts have been pending for an extended period and the company has been pursuing recovery through concerned departments, liaising officers, and legal representatives. The balance receivables primarily relate to regular business operations including H1 FY27 transactions and certain outstanding payments pertaining to the previous financial year.

Collection Update: The company received approximately ₹7 crores against outstanding receivables during the first week of Diwali. They expect greater clarity on the regular receivable position by December end.

UP Project Collection Cycle: The company operates through both directly awarded government contracts and subcontracted arrangements. Under the subcontracted model, collection depends on the payment cycle of both the government department and the intermediary contractor, which can extend the time taken to receive payment.

Operational and Strategic Updates

Network Expansion: The company added approximately 40-45 hospitals to its B2B empanelment network, taking the total number of hospital tie-ups to over 150.

Infrastructure Upgradation: Upgraded diagnostic infrastructure through installation of state-of-the-art imaging equipment. Established a CT scan facility through RG Stone collaboration in Faridabad. Expanding MRI capacity at Tilaknagar and developing dedicated laboratory infrastructure for genome sequencing.

New Facilities: Full-fledged Dwarka Diagnostic Center equipped with CT, MRI, ultrasound, and X-ray facilities targeting commissioning by end of November 2026, subject to necessary PCPNDT approval. The center is expected to generate annual revenue of approximately ₹5-6 crores in its initial year.

PPP Projects: Currently have 3 PPP projects in the pipeline covering CT, MRI, ultrasound, and X-ray services. Site preparation and machine orders completed with MoU signings pending.

Capital Expenditure: Planned capital expenditure of ₹20-25 crores for FY27, primarily towards diagnostic equipment and center development.

Management Guidance and Outlook

Growth Expectations: Medium-term growth expectations remain in the range of 20-25%.

Margin Targets: Expect EBITDA margins to normalize within 30-35% range and PAT margins around 20% over the next 2-3 years.

Cash Flow Target: Working towards achieving cash flow neutrality by the end of FY27.

Growth Drivers: Opportunities linked to commissioning of Dwarka facility, progression of 3 PPP projects, expansion of hospital partnerships, and addition of specialized diagnostic services including advanced imaging and genome sequencing.

Q&A Session Highlights

Receivables Aging: Apart from the ₹15 crore COVID-related receivables, approximately ₹15-16 crores are pending for more than 6 months.

PPP Project Timeline: Both Dwarka facility and government PPP projects expected to be operational by end of December 2026.

PPP Capital Commitment: Cumulative capital commitment for both projects is approximately ₹30 crores.

Geographical Expansion: Evaluating government tenders across India and have a couple of projects in the pipeline beyond Delhi/UP.

H2 FY27 Revenue Expectation: Approximately ₹60-65 crores revenue expected in H2 FY27.

FY28 Revenue: Cannot commit to specific numbers but growth trajectory expected to continue.

Revenue Mix Evolution: Focusing more on B2C and B2B segments, with target of maintaining 50-60% contribution from these segments.

Center Additions: After Dwarka, two more B2C centers planned. Currently have 26 diagnostic centers (up from 24 last year).

Capacity Utilization: Have around 30% capacity headroom which can be utilized across centers.

Competitive Positioning: Do not engage in aggressive bidding for tenders; only bid if feasible after thorough study.

Additional Information

The transcript is available on the company website at www.starimaging.in.